

highly pathogenic avian influenza A/H5N1 virus in BALB/c mice* (INFD-D-19-02234), to BMC Infectious Diseases.

As per our discussion, please upload the most recent version of your manuscript before we send it for peer-review.

Please submit your revised manuscript by accessing the following site:

https://www.editorialmanager.com/infd/

If you have forgotten your password, please use the 'Send Login Details' link on the login page at https://www.editorialmanager.com/infd/. For security reasons, your password will be reset.

Please note, if your manuscript is accepted you will not be able to make any changes to the authors, or order of authors, of your manuscript once the editor has accepted your manuscript for publication. If you wish to make any changes to authorship before you resubmit your revisions, please reply to this email and ask for a 'Request for change in authorship' form which should be completed by all authors (including those to be removed) and returned to this email address. Please ensure that any changes in authorship fulfil the criteria for authorship as outlined in BioMed Central's editorial policies (http://www.biomedcentral.com/about/editorialpolicies#authorship).

Once you have completed and returned the form, your request will be considered and you will be advised whether the requested changes will be allowed.

By resubmitting your manuscript you confirm that all author details on the revised version are correct, that all authors have agreed to authorship and order of authorship for this manuscript and that all authors have the appropriate permissions and rights to the reported data.

Please be aware that we may investigate, or ask your institute to investigate, any unauthorised attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

We look forward to receiving your revised manuscript before 25 Feb 2020.

Best wishes,

Leanne Archer BMC Infectious Diseases

https://bmcinfectdis.biomedcentral.com/

If improvements to the English language within your manuscript have been requested, you should have your manuscript reviewed by someone who is fluent in English. If you would like professional help in revising this manuscript, you can use any reputable English language editing service. We can recommend our affiliates Nature Research Editing Service (http://bit.ly/NRES_BS) and American Journal Experts (http://bit.ly/AJE_BS) for help with English usage. Please note that use of an editing service is neither a requirement nor a guarantee of publication. Free assistance is available from our English language tutorial (https://www.springer.com/gb/authors-editors/authorandreviewertutorials/writinginenglish) and our Writing resources (http://www.biomedcentral.com/getpublished/writing-resources). These cover common mistakes that occur when writing in English.

Editorial Policies

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements this will cause a delay whilst the issue is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all submissions to BMC Infectious Diseases must have a Declarations section which includes the mandatory sub-sections listed below. Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (https://bmcinfectdis.biomedcentral.com/

Where a mandatory section is not relevant to your study design or article type, for example, if your manuscript does not contain any individual persons data, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files. Please note that identifying/confidential patient data should not be shared. Authors who do not wish to share their data must state that data will not be shared, and provide reasons for this in the manuscript text. For further guidance on how to format this section, please refer to BioMed Central's editorial policies page - http://www.biomedcentral.com/submissions/editorial-policies#availability+of+data+and+materials.


Declarations


- Ethics approval and consent to participate
- Consent to publish
- Availability of data and materials
- Competing interests
- Funding
- Authors' Contributions
- Acknowledgements
- Authors' Information


Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at https://www.springernature.com/production-privacy-policy. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.


In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: https://www.editorialmanager.com/infd/login.asp?a=r). Please contact the publication office if you have any questions.













INFD-D-19-02234_...







Dear Dr. Shimizu,

Your manuscript "Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice" (INFD-D-19-02234R4) has been assessed by our reviewers. Based on these reports, and my own assessment as Editor, I am pleased to inform you that it is potentially acceptable for publication in BMC Infectious Diseases, once you have carried out some essential revisions suggested by our reviewers.

Their reports, together with any other comments, are below. Please also take a moment to check our website at https://www.editorialmanager.com/info/ for any additional comments that were saved as attachments.

If you are able to fully address these points, we would encourage you to submit a revised manuscript to BMC Infectious Diseases. Once you have made the necessary corrections, please submit a revised manuscript online at:

https://www.editorialmanager.com/infd/

If you have forgotten your password, please use the 'Send Login Details' link on the login page at https://www.editorialmanager.com/infd/. For security reasons, your password will be reset.

We request that a point-by-point response letter accompanies your revised manuscript. This letter must provide a detailed response to each reviewer/editorial point raised, describing what amendments have been made to the manuscript text and where these can be found (e.g. Methods section, line 12, page 5). If you disagree with any comments raised, please provide a detailed rebuttal to help explain and justify your decision.

Please also ensure that your revised manuscript conforms to the journal style, which can be found at the Submission Guidelines on the journal homepage.

A decision will be made once we have received your revised manuscript, which we expect by 23 Oct 2020.

Please note that you will not be able to add, remove, or change the order of authors once the editor has accepted your manuscript for publication.

Any proposed changes to the authorship must be requested during peer-review, and adhere to our criteria for authorship as outlined in BioMed Central's policies.

To request a change in authorship, please download the 'Request for change in authorship form' which can be found here - http://www.biomedcentral.com/about/editorialpolicies#authorship.

Please note that incomplete forms will be rejected.

Your request will be taken into consideration by the editor, and you will be advised whether any changes will be permitted.

Please be aware that we may investigate, or ask your institute to investigate, any unauthorized attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

We look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,
Taylor Hayes
on behalf of Sarah Gray
BMC Infectious Diseases
https://bmcinfectdis.biomedcentral.com/

Editor Comments:

- 1. Please indicate the authors Soetjipto Soetjipto and Gatot Soegiarto separately on your title page. 2. Please clearly indicate one corresponding author on your title page.
- 3. Please note the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript should be declared in the Funding section

4. Please consider the list of authors as it currently stands with reference to our guidelines regarding qualification for authorship (http://www.biomedcentral.com/submissions/editorial-policies#authorship).

Currently, the contributions of authors Jezzy R Dewantari, Aldise M Nastri, Laksmi Wulandari, Gatot Soegiarto, Soetjipto Soetjipto, Maria I Lusida do not automatically qualify them for authorship. In the section "Authors' contributions", please provide further clarifications on their contributions, and see our guidelines for authorship below.

An 'author' is generally considered to be someone who has made substantive intellectual contributions to a published study. Authors are expected to fulfil the criteria below (adapted from McNutt et al., Proceedings of the National Academy of Sciences, Feb 2018, 201715374; DOI: 10.1073/pnas.1715374115; licensed under CC BY 4.0);

Each author is expected to have made substantial contributions to the conception OR design of the work; OR the acquisition, analysis, OR interpretation of data; OR the creation of new software used in the work; OR have drafted the work or substantively revised it

AND to have approved the submitted version (and any substantially modified version that involves the author's contribution to the study);

AND to have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature

Acquisition of funding, collection of data or general supervision of the research group, alone, does not usually justify authorship. If these guidelines are not met, we would request the following change of authorship form be filled out and sent to our Editorial Office (BMCSeriesEditorial@biomedcentral.com) - https://www.biomedcentral.com/submissions/editorial-policies#authorship

Anyone who contributed towards the article who does not meet the criteria for authorship can be acknowledged in the 'Acknowledgements' section.

5. Please remove your ARRIVE checklist. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Additional files should remain uploaded as separate files. Please ensure that all figures, tables and additional/supplementary files are cited within the text.

We operate a transparent peer review process for this journal where reviewer reports are published with the article but the reviewers are not named (unless they opt in to include their name).

If improvements to the English language within your manuscript have been requested, you should have your manuscript reviewed by someone who is fluent in English. If you would like professional help in revising this manuscript, you can use any reputable English language editing service. We can recommend our affiliates Nature Research Editing Service (http://bit.ly/NRES_BS) and American Journal Experts (http://bit.ly/AJE_BS) for help with English usage. Please note that use of an editing service is neither a requirement nor a guarantee of publication. Free assistance is available from our English language tutorial (https://www.springer.com/gb/authors-editors/authorandreviewertutorials/writinginenglish) and our Writing resources (http://www.biomedcentral.com/getpublished/writing-resources). These cover common mistakes that occur when writing in English.

Editorial Policies

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Infectious Diseases must contain a Declarations section which includes the mandatory sub-sections listed below.

Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (https://bmcinfectdis. biomedcentral.com/

Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files.

Please note that identifying/confidential patient data should not be shared.

Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons.

For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below).

Declarations

Ethics approval and consent to participate

Consent to publish

Availability of data and materials

Competing interests

Fundina

Authors' Contributions

Acknowledgements

Further information about our editorial policies can be found at the following links: Ethical approval and consent

http://www.biomedcentral.com/about/editorialpolicies#Ethics

Availability of data and materials section:

up,//www.uiomedenii.ai.com/submissions/edutohat-policies#avaliabiiitytortuatatahutmatehais

Our flexible approach during the COVID-19 pandemic


If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.


This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at https://www.springernature.com/production-privacy-policy. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: https://www.editorialmanager.com/infd/login.asp?a=r). Please contact the publication office if you have any questions.







Dear Dr. Shimizu.

Your manuscript "Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice" (INFD-D-19-02234R5) has been assessed by our reviewers. Based on these reports, and my own assessment as Editor, I am pleased to inform you that it is potentially acceptable for publication in BMC Infectious Diseases, once you have carried out some essential revisions.

Once you have made the necessary corrections, please submit a revised manuscript online at:

https://www.editorialmanager.com/infd/

If you have forgotten your password, please use the 'Send Login Details' link on the login page at https://www.editorialmanager.com/infd/. For security reasons, your password will be reset.

Please also ensure that your revised manuscript conforms to the journal style, which can be found at the Submission Guidelines on the journal homepage.

A decision will be made once we have received your revised manuscript, which we expect by 17 Oct 2020.

Please note that you will not be able to add, remove, or change the order of authors once the editor has accepted your manuscript for publication.

Any proposed changes to the authorship must be requested during peer-review, and adhere to our criteria for authorship as outlined in BioMed Central's policies.

To request a change in authorship, please download the 'Request for change in authorship form' which can be found here -

http://www.biomedcentral.com/about/editorialpolicies#authorship.

Please note that incomplete forms will be rejected.

Your request will be taken into consideration by the editor, and you will be advised whether any changes will be permitted.

Please be aware that we may investigate, or ask your institute to investigate, any unauthorized attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

We look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,

Sarah Gray

BMC Infectious Diseases

https://bmcinfectdis.biomedcentral.com/

Editor Comments:

Thank you for amending your manuscript according to our requests and for providing further clarification. However, there are a few minor revisions that are necessary before we can accept the manuscript for publication, please see below.

1. Euthanasia Dosage

Please clarify your euthanasia/sacrifice methods, including injection dosages if applicable, methods used and rationale etc.

Please try to be as detailed as possible

Editorial Policies

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Infectious Diseases must contain a Declarations section which includes the mandatory sub-sections listed below.

Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (https://bmcinfectdis.biomedcentral.com/

).

Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files.

Please note that identifying/confidential patient data should not be shared.

Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons.

For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below).

Declarations

-

Ethics approval and consent to participate

*

Consent to publish

-

Availability of data and materials

Competing interests

.

Funding

3

Authors' Contributions

•

Acknowledgements

Further information about our editorial policies can be found at the following links:

Ethical approval and consent:

http://www.biomedcentral.com/about/editorialpolicies#Ethics

Availability of data and materials section:

http://www.biomedcentral.com/submissions/editorial-policies#availability+of+data+and+materials

Our flexible approach during the COVID-19 pandemic

If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at https://www.springernature.com/production-privacy-policy. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: https://www.editorialmanager.com/infd/login.asp?a=r). Please contact the publication office if you have any questions.



